Hypothesis: how do JAK2-inhibitors work in myelofibrosis

Ruben Mesa; Robert Peter Gale

doi:10.1016/j.leukres.2009.04.011

Hypothesis: how do JAK2-inhibitors work in myelofibrosis

Leuk Res. 2009 Sep;33(9):1156-7. doi: 10.1016/j.leukres.2009.04.011. Epub 2009 May 17.

Authors

Ruben Mesa¹, Robert Peter Gale

Affiliation

¹ Mayo Clinic, Scottsdale, AZ, USA.

PMID: 19450878
DOI: 10.1016/j.leukres.2009.04.011

Abstract

JAK2-inhibitors rapidly reduce spleen enlargement and clinical symptoms in persons with myelofibrosis but have little, if any, effect on the WBC, anemia, decreased platelets or bone marrow fibrosis. Also, JAK2-inhibitors are active in persons with and without the JAK2-mutation. Based on these and other data we suggest that the predominant effect of JAK2-inhibitors in persons with myelofibrosis is on normal rather than the abnormal clones.

MeSH terms

Humans
Janus Kinase 2 / antagonists & inhibitors*
Janus Kinase 2 / genetics
Mutation
Primary Myelofibrosis / drug therapy*
Protein Kinase Inhibitors / therapeutic use*

Substances

Protein Kinase Inhibitors
JAK2 protein, human
Janus Kinase 2